Navigation Links
NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
Date:3/7/2009

herpes viruses, yeasts and fungi. In addition, in Phase I human studies, NVC-422 has been shown to be safe and well-tolerated in the nose and bladder. Also, a Phase I trial with NVC-422 for the treatment of eye infections has commenced under the auspices of NovaBay partner Alcon, Inc. (NYSE: ACL).

Preclinical Study Details and Results

The purpose of the current study was to identify the optimal dosage and delivery of NVC-422 for treating Trichophyton mentagrophytes dermatophyte based on an established animal model previously used in the preclinical evaluation of terbinafine (Lamisil(R)) and itraconazole (Sporanox(R)). Guinea pigs were randomized to either placebo or doses of NVC-422 of 0.5%, 1.0%, 1.5%, or 2.0% applied to infected skin three times a day for seven days. Evaluation of clinical and mycological efficacies was performed three days after completion of treatment. Skin biopsies were performed for analysis.

Clinical efficacy rates of NVC-422 ranged from 23.7% for the lowest dose to 36.6% for the highest dose compared to 3.6% for placebo. Mycological efficacy rates ranged from 86.0% for the lowest dose to 97.9% for the highest dose compared to 53.8% for placebo. Furthermore, when compared to a previous clinical study, high dose NVC-422 showed superior clinical and mycological efficacy rates in this animal model compared to ciclopirox (Penlac(R)), a well-established topical antifungal agent (36.6% and 97.9% versus 7.2% and 85.0%, respectively).

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a mid-stage biopharmaceutical company developing first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells to treat and prevent a wide range of infections wi
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
3. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
4. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
5. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
6. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
9. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
10. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
11. Indevus Pharmaceuticals Announces PRO 2000 Found to Show Promise in Large HIV Prevention Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... The controversy surrounding the use of ... (procedures to remove uterine fibroids) continues, as a ... Johnson & Johnson,s Ethicon, Inc. unit, which was ... to the report published by The Wall Street ... is trying to determine what the company knew ...
(Date:5/28/2015)... , May 28, 2015 KaloBios Pharmaceuticals, Inc. ... Ronald A. Martell , to the position of ... of the KaloBios Board of Directors. In this new ... management team to refine and execute on the strategic ... company developing therapeutics for orphan oncology indications with high ...
(Date:5/28/2015)... Calif. , May 28, 2015 Compassion & ... Committee has approved a bill that would authorize the option ... vote was 5-2. ... (SB 128) , would allow mentally competent adults with six ... medication they could take to painlessly and peacefully end an ...
Breaking Medicine Technology:Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 2California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 3
... Neuralstem, Inc. (NYSE Amex: CUR ) announced ... trial to test its neuroregenerative small molecule drug, NSI-189, in ... the drug in healthy volunteers for safety and tolerability. Phase ... will test the safety and tolerability of NSI-189 in depressed ...
... Since its initial inception, Echosens has ... and strengthen its product range with the recent introduction ... Equipped with a new and more ergonomic tactile interface, ... latest FibroScan ® provides a reliable, accurate and ...
Cached Medicine Technology:Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 2Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 3Echosens: Launch of the FibroScan®502 Touch 2
(Date:5/28/2015)... May 28, 2015 The CEO and ... a just launched blog series which provides analysis on ... on the “R. Bruce Dalglish” profile on Blogger.com, this ... Bruce Dalglish’s corporate experience. , “Throughout my business ... cultures have upon the overall success of businesses,” stated ...
(Date:5/28/2015)... May 28, 2015 More than 300 ... will raise money to help the Muscular Dystrophy Association ... dystrophy and related life-threatening diseases that limit muscle strength ... mobile program. , From June 1 to June 30, ... customers the opportunity to help send local children affected ...
(Date:5/28/2015)... 28, 2015 ZH Healthcare (ZH), a ... it is releasing BlueEHS, the Electronic Health Solution, on ... for the benefit of all AWS users worldwide. ... first of its kind, Freemium, SaaS, Electronic Health Solution ... (EHR) with an integrated practice management system (PMS), e-Rx, ...
(Date:5/28/2015)... CompanionDx , a Houston-based ... it will present their integrated solution of next-generation ... annual American Society of Clinical Oncology (ASCO) in ... DNA in a patient’s tumor via a small ... changes or somatic mutations. Pharmacogenomics testing establishes a ...
(Date:5/28/2015)... Sexual Health Innovations, a nonprofit ... health and wellbeing in the United States, announced ... (USF) will be the first institution to adopt ... reporting system. , Callisto is designed to ... experience for college sexual assault survivors, to give ...
Breaking Medicine News(10 mins):Health News:R. Bruce Dalglish, CEO of Alliance Hospice, Introduces New Blog Series On Positive Corporate Culture 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 2Health News:sweetFrog and MDA Join Forces to Send Kids with Muscle Disease to Summer Camp 3Health News:BlueEHS, the Electronic Health Solution, now available on Amazon AWS Market place 2Health News:BlueEHS, the Electronic Health Solution, now available on Amazon AWS Market place 3Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 2Health News:University of San Francisco Becomes First in the Nation to Adopt College Sexual Assault Reporting System 3
... Reading a book can satisfy the crucial human need for ... 140 university students who were given 30 minutes to read ... Twilight or the wizard novel Harry Potter and ... of either vampires or wizards. The participants were then ...
... rising levels of cardiovascular disease (CVD) in the Asia Pacific ... the first time- the Society will send an official delegation ... The 18th edition of the APCC meeting will be ... 2011. The ESC deputation will present an educational programme called ...
... Chief of both the Division of Allergy and Inflammation and ... Center (BIDMC), is the recipient of an NIH MERIT ... A Professor of Medicine at Harvard Medical School, Weller received ... Functioning." An acronym for the Method to Extend Research ...
... is regarded as the most thorough way to ... procedure can also be painful. Scientists and engineers ... reduce patient discomfort while also ensuring the accuracy ... of Engineering led by Associate Professor of Mechanical ...
... accepted for publication in The Endocrine Society,s Journal of ... and white children with vitamin D deficiency both had higher ... levels of fat just under their skin and white children ... their internal organs. Studies in adults and children have ...
... The Scripps Research Institute and Tampa,s Moffitt Cancer ... study the formation and progression of prostate cancer. Of ... Scripps Research, with the remaining $138,380 supporting Moffitt Cancer ... Institutes of Health (NIH) will fund research to advance ...
Cached Medicine News:Health News:The European Society of Cardiology organizes educational program in Asia 2Health News:BIDMC's Peter Weller, M.D., receives NIH MERIT Award 2Health News:A less painful colonoscopy 2Health News:A less painful colonoscopy 3Health News:Vitamin D deficiency is associated with different types of obesity in black and white children 2Health News:Scripps Research wins more than $2 million to study prostate cancer 2
The RT-PLUS Solution is an axially supported rotation knee prosthesis for cemented implantation. The implant is available in three sizes, each of which can be combined with the next size up or down....
... Stabilized knee system was designed ... wear between all articulating surfaces ... associated with wear in order ... knee with normalized quadriceps and ...
... new generation of posterior stabilized knee ... the following: Patellar flange mates with ... machined condyles assure precise, repeatable kinematics ... and patella to reduce wear. Constant ...
... System offers a femoral option and tibial ... action that engages at 60 degrees of ... roll-back motion and allow for 130 degrees ... conjunction with the femur is designed to ...
Medicine Products: